48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, K3
Market cap: $2.6B (2/04/2026)
Price: $14.57
To Announce 2025 Final Results
Highlights Publication of Phase III SACHI Results in The Lancet
Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
Total Voting Rights
Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
Announces Initiation of Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
No filings found
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Schedule 13D - Ownership Report
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis